NCT06760858View on ClinicalTrials.gov

A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer

RecruitingOBSERVATIONAL
Enrollment

122

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2029

Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab: 200mg IV, day 1, Q3W, for a total of 3 cycles.

DRUG

SOX

SOX: S-1 dosage based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 3 cycles.

DEVICE

HIPEC

HIPEC: Docetaxel: 120mg, day 1, day 3.

Trial Locations (2)

400038

RECRUITING

The Southwest hospital of AMU, Chongqing

400084

NOT_YET_RECRUITING

The Southwest hospital of AMU, Chongqing

All Listed Sponsors
lead

Southwest Hospital, China

OTHER